Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
We have developed an efficient pretargeting strategy for renal cell carcinoma (RCC) based on a biologically produced bispecific monoclonal antibody (bs-mAb). Tumor targeting with this 2-step pretargeting strategy in the NU-12 mouse RCC model was very efficient compared with other pretargeting strategies, possibly due to unique characteristics of the NU-12 tumor used in our studies. Here we describe the bs-mAb G250xDTIn-1 pretargeting strategy in 3 different RCC nude mouse models.


METHODS
Three different human RCC xenografts in nude mice (NU-12, SK-RC-1, and SK-RC-52 tumors) were pretargeted with 100 pmol bs-mAb G250xDTIn-1. Three days after administration of the bs-mAb, mice were injected intravenously with 4 pmol 111In-labeled bivalent peptide, diDTPA-FKYK (DTPA is diethylenetriaminepentaacetic acid). At 1, 4, 24, 48, and 72 h after injection of the radiolabeled peptide, the biodistribution of the radiolabel was determined. The 3 RCC tumors were characterized in vivo and in vitro for G250 antigen expression, vessel density, vascular volume, and vascular permeability and by targeting with 111In-/125I-labeled cG250 mAb.


RESULTS
Using the pretargeting strategy, relatively high uptake of the radiolabel was observed in all 3 tumor models (maximum uptake: SK-RC-1 [278 +/- 130 %ID/g (percentage injected dose per gram), 1 h after injection] > NU-12 [93 +/- 41 %ID/g, 72 h after injection] > SK-RC-52 [54 +/- 9 %ID/g, 4 h after injection]). Remarkably, uptake of the radiolabel in the tumor did not correlate with G250 antigen expression. The kinetics of the radiolabel in the tumor varied largely in the 3 RCC tumors: SK-RC-1 and SK-RC-52 tumors showed a washout of the 111In label from the tumor with time: only 30% of the radiolabel was retained in the tumor 3 d after injection, whereas the 111In label was fully retained in NU-12 tumors. Physiologic characteristics (vessel density, vascular volume, and vascular permeability) of the tumors may explain these differences.


CONCLUSIONS
G250 antigen-expressing tumors can be pretargeted very efficiently with the bs-mAb G250xDTIn-1. There was no correlation between G250 antigen expression and uptake of the radiolabel in the tumor using the pretargeting strategy or with directly labeled mAbs. Therefore, these studies show that physiologic characteristics of the tumor, such as vascular permeability, play a significant role in pretargeting.
van Schaijk
Frank G
FG
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands. F.vanSchaijk@nucmed.umcn.nl
Oosterwijk
Egbert
E
Molkenboer-Kuenen
Janneke D
JD
Soede
Annemieke C
AC
McBride
Bill J
BJ
Goldenberg
David M
DM
Oyen
Wim J G
WJ
Corstens
Frans H M
FH
Boerman
Otto C
OC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000532:radiotherapy; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000532:radiotherapy; D008657:Metabolic Clearance Rate; D051379:Mice; D008819:Mice, Nude; D009842:Oligopeptides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D009928:Organ Specificity; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D014018:Tissue Distribution
C500046:111In-diDTPA-FKYK; D000911:Antibodies, Monoclonal; D009842:Oligopeptides; D019275:Radiopharmaceuticals; D004369:Pentetic Acid